Finerenone reduced heart failure (HF) events and cardiovascular death in patients with HF and mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF). bit.ly/4dJCEIE #ESCCongress

This meta-analysis investigated the effects of mineralocorticoid receptor antagonists (MRAs) using data from nearly 14,000 patients with heart failure from four trials. bit.ly/4cKKQHn #ESCCongress

Finerenone improved outcomes in two trials in patients with chronic kidney disease with type 2 diabetes and in a trial in patients with heart failure with mildly reduced or preserved ejection fraction. bit.ly/3AJNTSK #ESCCongress

There was no difference in complications in patients who fasted or did not fast before cardiac catheterisation procedures requiring conscious sedation, according to late-breaking research presented at #ESCCongress bit.ly/3Moy9al

In a large meta-analysis, complete revascularisation reduced cardiovascular events compared with culprit-only revascularisation in older patients with a myocardial infarction and multivessel disease at 4 years. bit.ly/3Mo1O3p #ESCCongress

The SENIOR-RITA trial showed significant reduction in the risk of non-fatal MIs and subsequent revascularisation procedures with an invasive vs. a conservative strategy. bit.ly/3Mm9SBX #ESCCongress

Atrial fibrillation screening with a wearable ECG device increased diagnoses by over 50%, but did not significantly reduce the rate of hospitalisation for stroke compared to usual care. bit.ly/3AKg3NB #ESCCongress

Mass screening for atrial fibrillation using single-lead ECG together w/ simple blood test for #heartfailure biomarker doesn't lower risk of ischaemic stroke or systemic embolism (blood clot) for adults aged 75-76 years after 5 years follow-up bit.ly/4g2ua0S #ESCCongress

MIRACLE-AF randomised cluster trial reveals success of novel telemedicine-supported, village doctor-led approach to managing atrial fibrillation in rural China. bit.ly/4dGBCNt #ESCCongress

SUPPRESS-AF trial finds performing additional ablations on top of standard treatment does not enhance the long-term success rate in patients with persistent atrial fibrillation—the most common type of heart rhythm disorder bit.ly/4dXVZp8 #ESCCongress

CRABL-HF -CRABL-HF trial finds cryoballoon ablation is as safe and effective as radiofrequency ablation with added benefit of shorter procedure time with less hemodynamic load from ablation. bit.ly/3XqVlva #ESCCongress

SHAM-PVI trial finds common ablation procedure significantly reduces time in #atrialfibrillation compared to sham procedure. bit.ly/3yNOzpN #ESCCongress

OCCUPI randomised trial finds optical coherence tomography significantly improves clinical outcomes and enhances safety and effectiveness of coronary stenting. bit.ly/3Z55m2a #ESCCongress

INFINITY-SWEDEHEART trial comparing the novel bioadaptor system to a contemporary drug-eluting stent (DES) demonstrates non-inferiority at 1 year and sustained reduction in target lesion failure from 6 months to 1 year. bit.ly/4cF6JYw #ESCCongress

REC­CAGEFREE I trial finds drug-coated balloon angioplasty less effective than second generation drug-eluting stents for previously untreated non-complex coronary lesions. bit.ly/4dDPbNV #ESCCongress

Randomised controlled trial finds novel point-of-care heart attack test is safe and could reduce length of stay in emergency department for some patients. bit.ly/4dG5NVb #ESCCongress

Trial finds that using AI to aid clinical decision making in identifying and managing myocardial infarction in patients presenting to the emergency department with suspected cardiac conditions does not improve cardiovascular outcomes. bit.ly/3MqNt6A #ESCCongress

Large UK randomised trial finds using AI to aid clinical decision-making in stress echocardiography showed no meaningful differences in all comers with suspected heart disease, but may improve decision making for less-experienced clinicians #ESCCongress bit.ly/3X7fwwK

ESC Congress 2024 reaches pre-COVID delegate numbers: 32,000 participants attend the world’s leading cardiovascular congress #ESCCongress bit.ly/4dRL14V #CVD #CardioX #medX #COVID

ESC Congress 2024 reaches pre-COVID delegate numbers: 32,000 participants attend the world’s leading cardiovascular congress. More about the congress highlights: bit.ly/3MxIeBT #ESCCongress